NCT00701597View on ClinicalTrials.gov

Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2007

Conditions
GlaucomaBlood Flow Velocity
Interventions
DRUG

bosentan

Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days

Trial Locations (1)

A-1090

Department of Clinical Pharmacology, Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00701597 - Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma | Biotech Hunter | Biotech Hunter